PRCT
Another $27 million vote of confidence
Chicago Capital apparently looked at PROCEPT BioRobotics and said, “Yeah, we’ll take more of that.” The firm added 969,592 shares, an estimated $27.32 million stake based on the average share price in Q1 2026.
Why you should care
This isn’t a new gadget or a courtroom drama — it’s a reminder that serious money is still backing PRCT. When a fund doubles down this hard, it can signal conviction in the company’s growth story, even if the stock hasn’t exactly been throwing confetti lately.
The investor read
For shareholders, moves like this can matter because they may:
- add a little momentum to the stock narrative,
- suggest a larger investor sees value in the setup,
- and put PROCEPT back on the radar for anyone tracking institutional ownership changes.
Of course, one fund buy doesn’t magically make the fundamentals better. But in a market where everyone loves to say they’re “long-term,” Chicago Capital just showed its work.
Big picture: sometimes the quietest headlines are the loudest clues — and this one says a big investor is still willing to put real money behind PRCT.